Abstract:
Bronchopulmonary dysplasia (BPD) is the most common chronic respiratory disorder affecting infants born prematurely. Roughly 20% of significant cases are accompanied by pulmonary hypertension (PAH). Little is known about the long-term outcomes of affected infants, and the present day management paradigms are seldom based on evidence, but are a distillate of individual or institutional preferences and show tremendous variability in practice. This presentation will describe the relationship of PAH to BPD; the pathogenesis of PAH in BPD; explain what is currently known about the natural history of PAH in infants with BPD; describe current management practices; help to determine if infants with BPD and PAH actually require pharmacologic intervention; review available treatment options, side effects, and complications of treatment; and will examine the evidence base; and conclude with a summary of the current knowledge gaps.
Audience Take Away Notes:
• Understand the relationship of PAH to BPD
• Realize the limited evidence base for determining treatment
• Review available treatment options
• Comprehend the present knowledge gaps and need for more research
